Crotoxin

Drug Profile

Crotoxin

Alternative Names: CB24; Cytotoxic PLA2; NSC-624244

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ventech
  • Developer Celtic Biotech; Celtic Biotech Iowa
  • Class Antineoplastics; Venoms
  • Mechanism of Action Apoptosis stimulants; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer

Most Recent Events

  • 18 Jul 2017 Celtic Biotech re-initiates enrolment in a phase I trial in Cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in France (IV) (NCT01481532)
  • 10 Mar 2017 Phase-II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in France (IV)
  • 13 Feb 2015 Celtic Biotech suspends enrolment in a phase I trial in Cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in France (IV) (NCT01481532)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top